Show Summary Details
Page of

Diamorphine 

Diamorphine
Chapter:
Diamorphine
Author(s):

Janet R. Hardy

and Columba Quigley

DOI:
10.1093/med/9780199236640.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 October 2020

Chapter 16 discusses Diamorphine (di-acetyl morphine, heroin), a semisynthetic derivative of morphine. It is not an active drug in its own right, but a pro-drug or opioid delivery system. The active metabolites 6-monoacetylmorphine (6-AM) and morphine are responsible for the analgesic effects of the drug. Diamorphine was first produced commercially in the late 1890s as a treatment for a variety of respiratory conditions including dyspnoea, pharyngitis, laryngitis, bronchitis, asthma, and tuberculosis. It was marketed by the Bayer Company under the trade name ‘heroin’. It was also recommended as a remedy for morphine dependence. In 1924 it was banned from medicinal use in the USA when its potential for abuse and addiction was recognized. Diamorphine is used widely and remains the parenteral opioid of choice for the treatment of chronic cancer pain in the UK, but is not used elsewhere because of these concerns.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.